12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga · 04/15 17:05
Gainers
- Mural Oncology (NASDAQ:MURA) stock increased by 145.5% to $2.53 during Tuesday's regular session. The market value of their outstanding shares is at $43.5 million.
- Skye Bioscience (NASDAQ:SKYE) stock moved upwards by 36.64% to $1.79. The market value of their outstanding shares is at $55.4 million.
- Dogwood Therapeutics (NASDAQ:DWTX) stock moved upwards by 32.57% to $3.98. The company's market cap stands at $7.6 million.
- Phio Pharma (NASDAQ:PHIO) shares increased by 29.47% to $2.85. The market value of their outstanding shares is at $13.6 million.
- Verve Therapeutics (NASDAQ:VERV) shares increased by 24.51% to $5.13. The company's market cap stands at $455.5 million.
- Aptorum Gr (NASDAQ:APM) stock rose 21.12% to $0.99. The company's market cap stands at $7.0 million.
Losers
- Spruce Biosciences (NASDAQ:SPRB) stock declined by 55.9% to $0.14 during Tuesday's regular session. The market value of their outstanding shares is at $5.7 million. The company's, Q4 earnings came out today.
- MetaVia (NASDAQ:MTVA) stock declined by 37.78% to $1.15. The company's market cap stands at $9.9 million.
- MSP Recovery (NASDAQ:MSPR) shares decreased by 22.27% to $2.2. The market value of their outstanding shares is at $4.6 million.
- Impact BioMedical (AMEX:IBO) shares declined by 22.26% to $0.37. The market value of their outstanding shares is at $4.2 million.
- Geovax Labs (NASDAQ:GOVX) shares decreased by 21.73% to $0.84. The company's market cap stands at $7.9 million.
- Sharps Technology (NASDAQ:STSS) stock fell 19.3% to $0.03. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.